Premium
Effect of silencing of mediator of DNA damage checkpoint protein 1 on the growth of oral squamous cell carcinoma in vitro and in vivo
Author(s) -
Zhang Xiaoying,
Hu Fengling,
Liu Liuhui,
Xu Bin
Publication year - 2019
Publication title -
european journal of oral sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.802
H-Index - 93
eISSN - 1600-0722
pISSN - 0909-8836
DOI - 10.1111/eos.12662
Subject(s) - gene knockdown , gene silencing , cancer research , cell growth , small interfering rna , in vivo , microbiology and biotechnology , carcinogenesis , rna interference , viability assay , chemistry , cell , blot , biology , cell culture , transfection , rna , cancer , biochemistry , gene , genetics
Mediator of DNA damage checkpoint protein 1 ( MDC 1) is involved in DNA damage repair and has been linked to tumor invasion, metastasis, and prognosis. This study investigated the effects of MDC 1 in oral squamous cell carcinoma ( OSCC ) in vitro and in vivo . RNA interference‐mediated knockdown of MDC 1 was performed in two OSCC cell lines (Tca‐8113 and KB ). Real‐time PCR and western blotting were performed to determine expression of mRNA and protein, respectively, of MDC 1. Cell viability was assessed using the MTT assay. Colony‐formation assays were performed by staining with 0.5% crystal violet. Cell migration and invasion were detected by Transwell assays. The role of MDC 1 in OSCC was examined in vivo via injection of Tca‐8113 cells transfected with MDC1 small interfering (si)RNA or negative‐control siRNA into a mouse xenograft model of OSCC . Our results showed that MDC 1 knockdown decreased cell proliferation. Inhibition of MDC 1 decreased colony formation of Tca‐8113 and KB cells by 62% and 68%, respectively, and MDC 1 knockdown reduced the number of migratory and invasive cells compared with the control group. Moreover, the xenograft mouse model of MDC 1 knockdown showed reduced tumor growth. Our study suggests that MDC 1 plays a role in tumorigenesis and might be a potential target for the treatment of patients with OSCC .